| 药品名称 | Abetimus |
|---|---|
| 分子靶点 | Bifunctional tail protein |
| 药物类型 | Biotech |
| 研发阶段 | Investigational |
| 药物描述 | Abetimus is an immunosuppressant developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe. |
| 药物别名 | Abetimus |
| 治疗类别 | Antineoplastic and Immunomodulating Agents;Carbohydrates;Glycosides;Immunosuppressive Agents;Nucleic Acids, Nucleotides, and Nucleosides;Nucleotides;Polynucleotides;Selective Immunosuppressants |
| UNII号 | P3UVQ22SHK |
| CAS号 | 167362-48-3 |
| 适应症 | Investigated for use/treatment in kidney disease and systemic lupus erythematosus. |
| ATC代码 | L04AA22 |
扩展信息
